Symbols / CALA
CALA Chart
About
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Financial Services | Industry | Shell Companies | Market Cap | 974.00 |
| Enterprise Value | -1.44M | Income | -21.29M | Sales | — |
| Book/sh | -0.40 | Cash/sh | 5.22 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | -0.00 | P/C | — |
| EV/EBITDA | 0.03 | EV/Sales | — | Quick Ratio | 3.44 |
| Current Ratio | 3.60 | Debt/Eq | 8.17 | LT Debt/Eq | — |
| EPS (ttm) | -2.65 | EPS next Y | -1.35 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2022-11-14 17:00 | ROA | -56.29% |
| ROE | -114.14% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.87M |
| Shs Float | 4.83M | Short Float | 8.92% | Short Ratio | 0.78 |
| Short Interest | — | 52W High | 0.01 | 52W Low | 0.00 |
| Beta | -3.29 | Avg Volume | 666.00 | Volume | 315.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | -42.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-104.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2022-11-15 | down | Ladenburg Thalmann | Buy → Neutral | — |
| 2022-11-15 | down | SVB Leerink | Outperform → Market Perform | $2 |
| 2022-08-29 | up | HC Wainwright & Co. | Neutral → Buy | $8 |
| 2022-08-16 | main | SVB Leerink | — → Outperform | $18 |
- After decades of service, Marriott hands key regions to a new leadership trio - Stock Titan Fri, 09 Jan 2026 08
- Calithera Biosciences Stock Nosedives On Complete Liquidation, Dissolution - Yahoo Finance Mon, 09 Jan 2023 08
- Cala announces new ownership Legal & General agrees sale with Sixth Street and Patron - Sixth Street Wed, 18 Sep 2024 07
- Calithera Biosciences (CALA) Stock Price, News & Analysis $CALA - MarketBeat Fri, 12 Aug 2016 09
- Cala Health launches wearable hand-tremor therapy device for adults with Parkinson’s - Healio hu, 15 Jun 2023 07
- Five years in, Fort Worth rodeo’s escaramuza competition spotlights Mexican culture - Fort Worth Report Mon, 03 Feb 2025 08
- Escaramuza riders bring Mexican culture to the Fort Worth Stock Show and Rodeo - The Shorthorn hu, 05 Feb 2026 00
- Top digital health funding: VCs back AI assistants - Modern Healthcare News Fri, 13 Dec 2024 08
- 3 Penny Stocks With Surprisingly Superior Fundamentals - Nasdaq Fri, 09 Sep 2022 07
- Calla Lily Care and Growing Tips - Birds and Blooms Fri, 28 Jun 2024 07
- Another fun-packed weekend on tap at Fort Worth Stock Show & Rodeo - The Business Press hu, 26 Jan 2023 08
- Snom “The Americas” Announces the Promotion of Chad M. Collins to Senior Vice President of Sales for Snom and VTech Hospitality in the US & CALA Regions - Business Wire Fri, 05 Sep 2025 07
- 5 Best Penny Stocks To Invest In - Insider Monkey Fri, 10 Jun 2022 07
- TowerXchange’s who’s who in CALA towers: 2023 edition - capacityglobal.com Fri, 10 Oct 2025 11
- Marriott Announces Milestone Global Growth & Expansion in 2025 - TradingView ue, 27 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 |
| NormalizedEBITDA | -43.77M | -13.40M |
| TotalUnusualItems | 1.95M | -50.88M |
| TotalUnusualItemsExcludingGoodwill | 1.95M | -50.88M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -39.65M | -115.09M |
| ReconciledDepreciation | 255.00K | 280.00K |
| EBITDA | -41.82M | -64.28M |
| EBIT | -42.07M | -64.56M |
| NetInterestIncome | 477.00K | 345.00K |
| InterestIncome | 477.00K | 345.00K |
| NormalizedIncome | -41.60M | -64.21M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -39.65M | -115.09M |
| TotalExpenses | 42.07M | 74.31M |
| TotalOperatingIncomeAsReported | -42.07M | -115.43M |
| DilutedAverageShares | 3.69M | |
| BasicAverageShares | 3.69M | |
| DilutedEPS | -31.20 | |
| BasicEPS | -31.20 | |
| DilutedNIAvailtoComStockholders | -39.65M | -115.09M |
| AverageDilutionEarnings | -18.36M | 0.00 |
| NetIncomeCommonStockholders | -21.29M | -115.09M |
| OtherunderPreferredStockDividend | -18.36M | 0.00 |
| NetIncome | -39.65M | -115.09M |
| NetIncomeIncludingNoncontrollingInterests | -39.65M | -115.09M |
| NetIncomeContinuousOperations | -39.65M | -115.09M |
| PretaxIncome | -39.65M | -115.09M |
| OtherIncomeExpense | 1.95M | -50.88M |
| SpecialIncomeCharges | 0.00 | -50.88M |
| OtherSpecialCharges | 50.88M | |
| GainOnSaleOfSecurity | 1.95M | |
| NetNonOperatingInterestIncomeExpense | 477.00K | 345.00K |
| InterestIncomeNonOperating | 477.00K | 345.00K |
| OperatingIncome | -42.07M | -64.56M |
| OperatingExpense | 42.07M | 74.31M |
| ResearchAndDevelopment | 28.53M | 53.45M |
| SellingGeneralAndAdministration | 13.54M | 20.85M |
| GeneralAndAdministrativeExpense | 13.54M | 20.85M |
| OtherGandA | 13.54M | 20.85M |
| TotalRevenue | 0.00 | 9.75M |
| OperatingRevenue | 0.00 | 9.75M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| OrdinarySharesNumber | 4.87M | 3.86M |
| ShareIssued | 4.87M | 3.86M |
| TotalDebt | 1.67M | 3.04M |
| TangibleBookValue | -1.95M | 8.38M |
| InvestedCapital | -1.95M | 8.38M |
| WorkingCapital | 19.23M | 47.45M |
| NetTangibleAssets | 20.39M | 8.38M |
| CapitalLeaseObligations | 1.67M | 3.04M |
| CommonStockEquity | -1.95M | 8.38M |
| PreferredStockEquity | 22.34M | |
| TotalCapitalization | 20.39M | 8.38M |
| TotalEquityGrossMinorityInterest | 20.39M | 8.38M |
| StockholdersEquity | 20.39M | 8.38M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | |
| RetainedEarnings | -512.62M | -491.33M |
| AdditionalPaidInCapital | 510.67M | 499.71M |
| CapitalStock | 22.34M | 0.00 |
| CommonStock | 0.00 | 0.00 |
| PreferredStock | 22.34M | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 8.28M | 56.37M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 894.00K | 42.37M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 40.70M |
| DerivativeProductLiabilities | 758.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 136.00K | 1.67M |
| LongTermCapitalLeaseObligation | 136.00K | 1.67M |
| CurrentLiabilities | 7.39M | 14.01M |
| OtherCurrentLiabilities | 193.00K | 45.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.53M | 1.37M |
| CurrentCapitalLeaseObligation | 1.53M | 1.37M |
| PayablesAndAccruedExpenses | 5.67M | 12.59M |
| CurrentAccruedExpenses | 4.93M | 8.94M |
| Payables | 732.00K | 3.65M |
| AccountsPayable | 732.00K | 3.65M |
| TotalAssets | 28.68M | 64.76M |
| TotalNonCurrentAssets | 2.05M | 3.30M |
| OtherNonCurrentAssets | 270.00K | 270.00K |
| NetPPE | 1.78M | 3.03M |
| AccumulatedDepreciation | -3.53M | -3.29M |
| GrossPPE | 5.32M | 6.33M |
| Leases | 1.23M | 1.23M |
| OtherProperties | 3.36M | 4.36M |
| MachineryFurnitureEquipment | 718.00K | 734.00K |
| Properties | 0.00 | 0.00 |
| CurrentAssets | 26.62M | 61.45M |
| OtherCurrentAssets | 1.17M | 1.92M |
| PrepaidAssets | 1.92M | |
| Receivables | 0.00 | |
| AccountsReceivable | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 25.45M | 59.54M |
| OtherShortTermInvestments | 0.00 | |
| CashAndCashEquivalents | 25.45M | 59.54M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| FreeCashFlow | -43.74M | -66.45M |
| IssuanceOfCapitalStock | 9.64M | 10.66M |
| CapitalExpenditure | -133.00K | -147.00K |
| EndCashPosition | 25.72M | 59.81M |
| BeginningCashPosition | 59.81M | 107.59M |
| ChangesInCash | -34.09M | -47.78M |
| FinancingCashFlow | 9.65M | 10.67M |
| CashFlowFromContinuingFinancingActivities | 9.65M | 10.67M |
| NetOtherFinancingCharges | -173.00K | |
| ProceedsFromStockOptionExercised | 16.00K | 177.00K |
| NetCommonStockIssuance | 9.64M | 10.66M |
| CommonStockIssuance | 9.64M | 10.66M |
| InvestingCashFlow | -133.00K | 7.85M |
| CashFlowFromContinuingInvestingActivities | -133.00K | 7.85M |
| NetInvestmentPurchaseAndSale | 0.00 | 8.00M |
| SaleOfInvestment | 0.00 | 8.00M |
| PurchaseOfInvestment | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -133.00K | -147.00K |
| PurchaseOfPPE | -133.00K | -147.00K |
| OperatingCashFlow | -43.61M | -66.30M |
| CashFlowFromContinuingOperatingActivities | -43.61M | -66.30M |
| ChangeInWorkingCapital | -7.43M | -3.40M |
| ChangeInOtherCurrentLiabilities | -1.37M | -1.18M |
| ChangeInOtherCurrentAssets | 0.00 | 0.00 |
| ChangeInPayablesAndAccruedExpense | -6.79M | -3.87M |
| ChangeInAccruedExpense | -3.88M | -5.52M |
| ChangeInPayable | -2.92M | 1.66M |
| ChangeInAccountPayable | -2.92M | 1.66M |
| ChangeInPrepaidAssets | 742.00K | 96.00K |
| ChangeInReceivables | 0.00 | 1.54M |
| OtherNonCashItems | 1.13M | 41.65M |
| StockBasedCompensation | 4.03M | 10.26M |
| AmortizationOfSecurities | 0.00 | 2.00K |
| DepreciationAmortizationDepletion | 255.00K | 280.00K |
| DepreciationAndAmortization | 255.00K | 280.00K |
| Depreciation | 255.00K | 280.00K |
| OperatingGainsLosses | -1.95M | |
| GainLossOnInvestmentSecurities | -1.95M | |
| NetIncomeFromContinuingOperations | -39.65M | -115.09M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CALA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|